MONTREAL, Quebec — September 10, 2026 — Leads & Copy — Cannara Biotech Inc. announced an $80 million syndicated credit facility with Bank of Montreal and The Toronto-Dominion Bank, increasing its borrowing capacity by $30 million. The agreement, which primarily refinances existing debt, provides additional liquidity for working capital and strategic investments.
Bank of Montreal will continue as the administrative agent, syndication agent, and sole bookrunner. The Toronto-Dominion Bank joins as a co-lead arranger, expanding Cannara’s banking relationships and institutional support.
The new credit facility extends Cannara’s debt maturity to December 31, 2029, from December 31, 2027. It also increases the company’s committed revolving capacity from $10 million to $40 million. These adjustments are intended to support ongoing capital investments at Cannara’s Valleyfield facility, including the development of a new post-processing centre designed to support EU-GMP certification and the activation of additional cultivation zones.
Zohar Krivorot, Founder and Chief Executive Officer of Cannara, stated that the syndicated credit facility signifies a strong endorsement of the company’s business and its consistent profitable growth. He added that the addition of TD alongside BMO broadens the company’s banking platform and provides the financial capacity for future growth in Canada and internationally.
Niko Sosiak, Chief Operating Officer of Cannara, highlighted that the refinancing strengthens the company’s capital structure by increasing revolving capacity, extending maturity, and consolidating existing facilities into a more flexible package.
Nicholas Fozard, Cannara’s Acting Chief Financial Officer, expressed his anticipation in working with the leadership team to invest in growth priorities and build upon the company’s financial foundation with the Restated Credit Facility now in place.
Key aspects of the Restated Credit Facility include a $40 million term loan to refinance existing term loan, capital expenditures, and revolving credit facilities, with remaining proceeds allocated for capital expenditures at the Valleyfield facility. Additionally, a $40 million revolving credit facility, an increase from $10 million, is available for ordinary working capital and general corporate needs.
Revised financial covenants within the Restated Credit Facility are designed to provide Cannara with enhanced flexibility and liquidity for its expansion program at the Valleyfield facility. The company’s obligations under the original credit agreement continue uninterrupted under the new terms, with all other original terms and conditions remaining in effect.
Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis products. The company operates two large facilities in Quebec, totaling over 1.6 million square feet, with a potential annualized cultivation output of 100,000 kg.
Source: Cannara Biotech Inc.
